Structure-based ligand design and the promise held for antiprotozoan drug discovery

    Research output: Contribution to journalReview article

    39 Citations (Scopus)

    Abstract

    The development of the pharmaceutical industry, driven by progress in chemistry, biology, and technology, ranks as one of the most successful of human endeavors. However, serious health problems persist, among which are diseases caused by protozoan parasites, largely ignored in modern times. Advances in genomic sciences, molecular and structural biology, and computational and medicinal chemistry now set the scene for a renewed assault on such infections. A structure-centric approach to support discovery of antiparasitic compounds promises much. Current strategies and benefits of a structure-based approach to support early stage drug discovery will be described.

    Original languageEnglish
    Pages (from-to)11749-11753
    Number of pages5
    JournalJournal of Biological Chemistry
    Volume284
    Issue number18
    DOIs
    Publication statusPublished - 1 May 2009

    Keywords

    • PLASMODIUM-FALCIPARUM
    • NATURAL-PRODUCTS
    • TARGETS
    • DISEASES
    • LEISHMANIASIS
    • DRUGGABILITY
    • TRYPANOSOMA
    • LIBRARIES
    • BIOLOGY
    • TRENDS

    Cite this

    @article{8d47acf8f76e481386fe8bc4446cce09,
    title = "Structure-based ligand design and the promise held for antiprotozoan drug discovery",
    abstract = "The development of the pharmaceutical industry, driven by progress in chemistry, biology, and technology, ranks as one of the most successful of human endeavors. However, serious health problems persist, among which are diseases caused by protozoan parasites, largely ignored in modern times. Advances in genomic sciences, molecular and structural biology, and computational and medicinal chemistry now set the scene for a renewed assault on such infections. A structure-centric approach to support discovery of antiparasitic compounds promises much. Current strategies and benefits of a structure-based approach to support early stage drug discovery will be described.",
    keywords = "PLASMODIUM-FALCIPARUM, NATURAL-PRODUCTS, TARGETS, DISEASES, LEISHMANIASIS, DRUGGABILITY, TRYPANOSOMA, LIBRARIES, BIOLOGY, TRENDS",
    author = "Hunter, {William N.}",
    year = "2009",
    month = "5",
    day = "1",
    doi = "10.1074/jbc.R800072200",
    language = "English",
    volume = "284",
    pages = "11749--11753",
    journal = "Journal of Biological Chemistry",
    issn = "0021-9258",
    publisher = "American Society for Biochemistry and Molecular Biology",
    number = "18",

    }

    Structure-based ligand design and the promise held for antiprotozoan drug discovery. / Hunter, William N.

    In: Journal of Biological Chemistry, Vol. 284, No. 18, 01.05.2009, p. 11749-11753.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Structure-based ligand design and the promise held for antiprotozoan drug discovery

    AU - Hunter, William N.

    PY - 2009/5/1

    Y1 - 2009/5/1

    N2 - The development of the pharmaceutical industry, driven by progress in chemistry, biology, and technology, ranks as one of the most successful of human endeavors. However, serious health problems persist, among which are diseases caused by protozoan parasites, largely ignored in modern times. Advances in genomic sciences, molecular and structural biology, and computational and medicinal chemistry now set the scene for a renewed assault on such infections. A structure-centric approach to support discovery of antiparasitic compounds promises much. Current strategies and benefits of a structure-based approach to support early stage drug discovery will be described.

    AB - The development of the pharmaceutical industry, driven by progress in chemistry, biology, and technology, ranks as one of the most successful of human endeavors. However, serious health problems persist, among which are diseases caused by protozoan parasites, largely ignored in modern times. Advances in genomic sciences, molecular and structural biology, and computational and medicinal chemistry now set the scene for a renewed assault on such infections. A structure-centric approach to support discovery of antiparasitic compounds promises much. Current strategies and benefits of a structure-based approach to support early stage drug discovery will be described.

    KW - PLASMODIUM-FALCIPARUM

    KW - NATURAL-PRODUCTS

    KW - TARGETS

    KW - DISEASES

    KW - LEISHMANIASIS

    KW - DRUGGABILITY

    KW - TRYPANOSOMA

    KW - LIBRARIES

    KW - BIOLOGY

    KW - TRENDS

    U2 - 10.1074/jbc.R800072200

    DO - 10.1074/jbc.R800072200

    M3 - Review article

    VL - 284

    SP - 11749

    EP - 11753

    JO - Journal of Biological Chemistry

    JF - Journal of Biological Chemistry

    SN - 0021-9258

    IS - 18

    ER -